JY
FULC icon

Jeff Yass’s Fulcrum Therapeutics FULC Stock Holding History

Jeff Yass’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$264K Sell
72,000
-78,000
-52% -$474K ﹤0.01% 11339
2026
Q1 		$1.15M Buy
150,000
+9,500
+7% +$88.1K ﹤0.01% 7517
2025
Q4 		$1.59M Buy
140,500
+74,000
+111% +$753K ﹤0.01% 6116
2025
Q3 		$612K Sell
66,500
-58,500
-47% -$423K ﹤0.01% 8502
2025
Q2 		$860K Buy
125,000
+91,200
+270% +$488K ﹤0.01% 7818
2025
Q1 		$97.3K Sell
33,800
-239,200
-88% -$879K ﹤0.01% 11557
2024
Q4 		$1.28M Sell
273,000
-283,900
-51% -$1.05M ﹤0.01% 6352
2024
Q3 		$1.99M Buy
556,900
+425,600
+324% +$3.16M ﹤0.01% 5277
2024
Q2 		$814K Sell
131,300
-174,200
-57% -$1.32M ﹤0.01% 7082
2024
Q1 		$2.88M Buy
305,500
+1,500
+0.5% +$13.4K ﹤0.01% 4599
2023
Q4 		$2.05M Sell
304,000
-400
-0.1% -$1.77K ﹤0.01% 5286
2023
Q3 		$1.35M Buy
304,400
+18,400
+6% +$80.4K ﹤0.01% 5952
2023
Q2 		$944K Sell
286,000
-12,000
-4% -$35.3K ﹤0.01% 6813
2023
Q1 		$849K Buy
298,000
+54,600
+22% +$489K ﹤0.01% 7246
2022
Q4 		$1.77M Sell
243,400
-33,700
-12% -$220K ﹤0.01% 4941
2022
Q3 		$2.24M Buy
277,100
+71,200
+35% +$510K ﹤0.01% 4682
2022
Q2 		$1.01M Buy
205,900
+116,200
+130% +$1.14M ﹤0.01% 6518
2022
Q1 		$2.12M Buy
89,700
+43,400
+94% +$614K ﹤0.01% 5350
2021
Q4 		$819K Sell
46,300
-9,400
-17% -$186K ﹤0.01% 7822
2021
Q3 		$1.57M Buy
+55,700
New +$1.06M ﹤0.01% 6362

Other funds holding FULC

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jeff Yass's FULC Position: Q2 2026 in Review

Jeff Yass increased its Fulcrum Therapeutics (FULC) stake by 1,065% in Q2 2026, buying an estimated $6.57M and bringing the position to 1,180,946 shares worth $4.32M. The position accounts for ﹤0.01% of the portfolio, ranked #4908.

Jeff Yass first reported a position in FULC in Q3 2019 and has held it in 18 quarters since. The position peaked at $5.3M in Q1 2024. 154 funds tracked by Wall St. Rank hold FULC as of Q2 2026.

  • Jeff Yass held 1,180,946 shares of Fulcrum Therapeutics worth $4.32M as of Q2 2026.
  • Jeff Yass bought 1,079,610 Fulcrum Therapeutics shares in Q2 2026, an estimated $6.57M.
  • Fulcrum Therapeutics made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #4908 holding.
  • Jeff Yass first reported a position in Fulcrum Therapeutics in Q3 2019 and has held it in 18 quarters since.
  • Jeff Yass's Fulcrum Therapeutics position peaked at $5.3M in Q1 2024.
  • 154 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.